Jump to content

4'-Methyl-α-pyrrolidinopropiophenone

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Aethyta (talk | contribs) at 12:10, 23 May 2016. The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

For other uses, see MPPP (disambiguation).
Not to be confused with desmethylprodine (opioid drug with acronym MPPP), MPTP (neurotoxic impurity of desmethylprodine synthesis) or MPP+ (neurotoxic metabolite of MPTP).
4'-Methyl-α-pyrrolidinopropiophenone
Legal status
Legal status
Identifiers
  • (RS)-1-(4-methylphenyl)-2-(1-pyrrolidinyl)-1-propanone
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC14H19NO
Molar mass217.3081 g/mol g·mol−1
3D model (JSmol)
  • CC1=CC=C(C=C1)C(=O)C(C)N2CCCC2
  • InChI=1S/C14H19NO/c1-11-5-7-13(8-6-11)14(16)12(2)15-9-3-4-10-15/h5-8,12H,3-4,9-10H2,1-2H3
  • Key:APSJUNFBAXIXLK-UHFFFAOYSA-N

4'-Methyl-α-pyrrolidinopropiophenone (4-MePPP, MPPP or MαPPP) is a stimulant drug. It is structurally very similar to α-PPP, with only one added methyl group in the para position on the phenyl ring. 4-MePPP was sold in Germany as a designer drug in the late 1990s and early 2000s,[1][2][3] along with a number of other pyrrolidinophenone derivatives.[4][5] Although it has never achieved the same international popularity as its better-known relations α-PPP and MDPV, 4-MePPP is still sometimes found as an ingredient of grey-market "bath salt" blends[6] such as "NRG-3".[6]

Legality

Sweden's public health agency suggested to classify 4-MePPP as hazardous substance on November 10, 2014.[7]

See also

References

  1. ^ Springer, D; Peters, FT; Fritschi, G; Maurer, HH (2002). "Studies on the metabolism and toxicological detection of the new designer drug 4'-methyl-alpha-pyrrolidinopropiophenone in urine using gas chromatography-mass spectrometry". Journal of Chromatography B. 773 (1): 25–33. doi:10.1016/S1570-0232(01)00578-5. PMID 12015267.
  2. ^ Springer, D; Paul, LD; Staack, RF; Kraemer, T; Maurer, HH (2003). "Identification of cytochrome p450 enzymes involved in the metabolism of 4'-methyl-alpha-pyrrolidinopropiophenone, a novel scheduled designer drug, in human liver microsomes". Drug metabolism and disposition: the biological fate of chemicals. 31 (8): 979–82. doi:10.1124/dmd.31.8.979. PMID 12867484.
  3. ^ Springer, D; Fritschi, G; Maurer, HH (2003). "Metabolism of the new designer drug alpha-pyrrolidinopropiophenone (PPP) and the toxicological detection of PPP and 4'-methyl-alpha-pyrrolidinopropiophenone (MPPP) studied in rat urine using gas chromatography-mass spectrometry". Journal of Chromatography B. 796 (2): 253–66. doi:10.1016/j.jchromb.2003.07.008. PMID 14581066.
  4. ^ Maurer, HH; Kraemer, T; Springer, D; Staack, RF (2004). "Chemistry, pharmacology, toxicology, and hepatic metabolism of designer drugs of the amphetamine (ecstasy), piperazine, and pyrrolidinophenone types: a synopsis". Therapeutic drug monitoring. 26 (2): 127–31. doi:10.1097/00007691-200404000-00007. PMID 15228152.
  5. ^ Staack, RF; Maurer, HH (2005). "Metabolism of designer drugs of abuse". Current drug metabolism. 6 (3): 259–74. doi:10.2174/1389200054021825. PMID 15975043.
  6. ^ a b Brandt SD, Freeman S, Sumnall HR, Measham F, Cole J (December 2010). "Analysis of NRG 'legal highs' in the UK: identification and formation of novel cathinones". Drug Testing and Analysis. 3 (9): 569–75. doi:10.1002/dta.204. PMID 21960541.
  7. ^ "Cannabinoider föreslås bli klassade som hälsofarlig vara". Retrieved 29 June 2015.


Stub icon

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=4%27-Methyl-α-pyrrolidinopropiophenone&oldid=721680679"